- Global Phase 2 Part 1 clinical trial results for the atopic dermat바카라사이트 정보is treatment candidate NuGel presented
- In-depth technical review of partners and Phase 2 Part 2 final data for NuGel expected to be secured in H1 2026
[by Jin, Yu Jeong] 바카라사이트 정보 announced on November 26 that it delivered presentations on the global Phase 2 Part 1 clinical trial data for its atopic dermatitis treatment candidate, NuGel, as well as the nonclinical results of its inflammasome inhibitor candidate targeting acne, rosacea, and diabetic foot ulcers at the 9th Dermatology Drug Development Summit (DDDS), a global forum dedicated to the development of new treatments for skin diseases, held in Boston, USA, from November 18 to 20.
DDDS is an industry-centered conference attended by major global pharmaceutical and biotechnology companies, including AbbVie, Amgen, Eli Lilly, Sanofi, Novartis, and Pfizer. The event is widely recognized as a partnership-oriented forum, fostering active dialogue on applied technological cooperation as well as business development and strategic collaborations.
바카라사이트 정보 stated that this presentation reinforced the clinical evidence and the global commercialization potential of its GPCR19-targeting inflammasome inhibitor, a novel drug candidate currently under development for the treatment of diverse dermatological conditions.
Of particular note, the company elaborated that, on the basis of this R&D milestone, it has secured a fundamental basis for extending the patent expiration period by approximately 20 years. 바카라사이트 정보 underscored that subsequent to its prior raw material R&D efforts, this achievement markedly reinforces long-term exclusivity and commercial value of its core pipeline, significantly elevating its technological competitiveness and further increasing its global commercialization potential.
NuGel is designed to modulate GPCR19 signaling, enabling simultaneous inhibition of both the initial and amplification phases of inflammasome activation. In a Phase 2 Part 2 clinical trial conducted in the United States earlier this year, 바카라사이트 정보 reported a favorable safety and tolerability profile compared to existing treatments in a multi-ethnic study population. Through this conference presentation, the company intends to maximize commercial viability by expanding therapeutic indications and patent extensions for a variety of dermatological conditions beyond atopic dermatitis.
바카라사이트 정보 also participated in the 6th Inflammatory Skin Disease Summit (ISDS), convened in New York from November 12 to 15. At the ISDS, the company presented progress on its pipeline of investigational novel drugs targeting inflammatory complexes for various dermatological conditions, with emphasis on technological differentiation and commercial marketability. ISDS, recognized as a leading international conference in inflammatory dermatology, serves as a major forum for discussing new drug mechanisms and clinical strategies in the field of inflammatory skin diseases.
바카라사이트 정보 announced that it is reinforcing strategic partnerships with global pharmaceutical companies, supported by its recent participation in two U.S.-based international dermatology conferences on the East Coast. The company indicated that it expects the ongoing in-depth technology review with its pharmaceutical partners to conclude in the first half of 2026 and that the commercial applicability of its technology is likely to become clearer once the final data from Phase 2 Part 2 clinical trials are available.
"At the ISDS and DDDS, discussions on the global stage extended beyond the mechanism of action, clinical data, and commercialization strategy of NuGel as a therapy for atopic dermatitis, additionally addressing our broader therapeutic programs for inflammatory diseases across multiple dermatological fields. We aim to accelerate novel drug development and technology commercialization through expanded global collaborations spanning the full lifecycle, from the preclinical stage through clinical development and commercialization," a Shaperon official said.
"The recent co-development agreement for a malaria vaccine, signed with MMV, a malaria research institute based in Switzerland, exemplifies our company’s R&D capabilities gaining recognition in the international public health field. Leveraging these global collaborations, we plan to expedite commercialization of our core pipeline," the official further added.